STOCK TITAN

State Street (VNDA) discloses 3.02M shares, 5.1% ownership on 13G

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

State Street Corporation reported beneficial ownership of 3,015,562 shares (5.1%) of Vanda Pharmaceuticals as of 03/31/2026 on a Schedule 13G. The filing shows shared voting power of 2,935,448 shares and shared dispositive power of 3,015,562 shares, with holdings held on behalf of multiple State Street advisory entities.

Positive

  • None.

Negative

  • None.

Insights

Large passive position disclosed by State Street at 5.1%.

State Street Corporation reports 3,015,562 shares beneficially owned (5.1%) as of 03/31/2026, with shared voting power of 2,935,448 shares. The filing is a Schedule 13G, which typically reflects passive investment management rather than an active acquisition.

The disclosure names affiliated managers such as SSGA Funds Management, Inc. and others; cash‑flow treatment and any plans for disposition are not stated in the excerpt. Subsequent filings would show any material change in ownership or voting intent.

Voting and dispositive splits signal agency-managed holdings.

The schedule lists shared voting power (2,935,448 shares) and shared dispositive power (3,015,562 shares), indicating holdings are managed across State Street investment vehicles. Item 6 is answered "Not applicable" for third‑party rights to proceeds, per the excerpt.

Because the filing is a 13G, the position is presented as passive; any change to active intent would require an amended filing under the applicable rules.

Report date (ownership as of) 03/31/2026 Ownership reporting date on Schedule 13G
Beneficial ownership 3,015,562 shares Amount beneficially owned reported by State Street
Percent of class 5.1% Percentage of Vanda Pharmaceuticals common stock
Shared voting power 2,935,448 shares Number of shares with shared power to vote
CUSIP 921659108 Identifier for Vanda Pharmaceuticals common stock
Schedule 13G regulatory
"Schedule 13G filing reporting passive beneficial ownership (first line)"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Beneficially owned financial
"Amount beneficially owned: 3015562.00"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Shared dispositive power regulatory
"Shared power to dispose or to direct the disposition of: 3,015,562"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





921659108

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G



STATE STREET CORPORATION
Signature:ELIZABETH SCHAEFER
Name/Title:SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
Date:05/12/2026

FAQ

What stake does State Street (VNDA) report on Schedule 13G?

State Street reports beneficial ownership of 3,015,562 shares, representing 5.1% of Vanda Pharmaceuticals as of 03/31/2026. The filing lists shared voting power of 2,935,448 shares and identifies several State Street advisory subsidiaries as holders.

Does the Schedule 13G indicate State Street plans to control Vanda Pharmaceuticals (VNDA)?

No explicit control intent is stated; the filing is a Schedule 13G, which typically indicates a passive position. The disclosure shows shared voting power and does not assert active control or a change in intent in the provided excerpt.

Which State Street entities are named as holders in the VNDA filing?

The filing identifies affiliated managers including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, and State Street Global Advisors Trust Company as relevant subsidiaries involved in the reported holdings.

When was the Schedule 13G for VNDA signed and by whom?

The excerpt shows the report signed by Elizabeth Schaefer, Senior Vice President and Chief Accounting Officer, with a signature date of 05/12/2026, while the ownership is reported as of 03/31/2026.